TELA Bio, Inc. (TELA) income statement
TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.69−0.04 (-5.27%)
Close on Nov 20, 2026Market cap $30.91MP/E –Yield –
TELA Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 67.8%
- Operating margin
- -42.6%
- Net margin
- -51.5%
- Return on equity, FY2025
- -223.4%
Financial strength
- Current ratio
- 2.99
- Debt to equity
- -3.53
- Debt to assets
- 93.9%
- Cash to current liabilities
- 167.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.39
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?